Zenabis Global’s (TSX:ZENA) cultivation output in August 2019 was 1,996 kg of dried cannabis, 40.9% greater than its revised design capacity and 26.4% greater than its Aug. 6 revised forecast output of 1,579 kg of dried...
Anika Therapeutics (NASDAQ: ANIK) launched its injectable hyaluronic acid (HA) enhanced bone repair therapy, TACTOSET, in the U.S. for the treatment of bone voids and other bone defects. TACTOSET is an injectable, HA...
The FDA approved Kadmon Holdings’ (NYSE:KDMN) generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. Wilson’s disease is a genetic disorder caused by...
Online continuing professional development provider, MDBriefCase Group (MDBC), is collaborating with Dr. David Strain, senior clinical lecturer at the University of Exeter and Dr. Mohamed Farghaly, associate professor...
OrthoSpin, a portfolio of company of The Trendlines Group (OTCQX:TRNLY; SGX:42T) received regulatory clearance from the FDA for its smart, robotic external fixation system for orthopedic treatments. The use of external...
The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...
William Blair initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and a fair value estimate of $48. The stock closed at $28.21 on Sept. 17. Axsome Therapeutics is focused on developing...
Kimberly Peery Stereotaxis (NYSE American:STXS) appointed Kimberly Peery as CFO, effective October 1, replacing Martin Stammer, who has accepted a position as CFO of a large professional services firm in the St. Louis...
William Blair launched coverage of Minerva Neurosciences (NASDAQ:NERV) with an “outperform” rating and fair value estimate of $26. The stock closed at $8.11 on Sept. 17. Minerva is developing therapies for mood...
iBio (NYSE AMERICAN:IBIO) advanced its collaboration with closely-held AzarGen Biotechnologies by initiating development of a plant-made rituximab for the South African market. iBio previously used its FastPharming...
Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients...
SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...